Dr. Berinstein on Combination Treatments for High-Risk and Recurrent Follicular Lymphoma

Video

Neil L. Berinstein, MD, professor, University of Toronto, Sunnybrook Health Sciences Centre, discusses combination treatments for patients with high-risk or recurrent follicular lymphoma.

Neil L. Berinstein, MD, professor, University of Toronto, Sunnybrook Health Sciences Centre, discusses combination treatments for patients with high-risk or recurrent follicular lymphoma.

High-dose therapy and stem cell transplants with immunotherapy is a very valuable treatment for patients with high-risk or recurrent follicular lymphoma, according to Berinstein.

Many patients relapse after their first initial frontline treatment for follicular lymphoma within the first year. However, due to this treatment, patients are now going without requiring further treatment for a median of 8 years, explains Berinstein.

Related Videos
Angela Jia, MD, PhD, of University Hospitals
Robert Wang, MD, of Fox Chase Cancer Center
Alexander Kutikov, MD, FACS, of Fox Chase Cancer Center
Roger Li, MD, of Moffitt Cancer Center
Joshua J. Meeks, MD, PhD, of Northwestern University Feinberg School of Medicine
Neal Shore, MD, FACS, of GenesisCare USA and Carolina Urologic Research Center
Mark D. Tyson, II, MD, MPH
Pasi A. Jänne, MD, PhD, discusses an exploratory analysis from the FLAURA2 trial of osimertinib plus chemotherapy in treatment-naive, EGFR-mutant NSCLC.
Eric S. Christenson, MD